European Radiology profiles Seno Medical's breast cancer diagnostic technology
advertisement

European Radiology profiles Seno Medical's breast cancer diagnostic technology

Press releases may be edited for formatting or style | June 19, 2019 Molecular Imaging Women's Health
SAN ANTONIO, June 19, 2019 /PRNewswire/ -- Additional research appearing in the June online issue (open access) of European Radiology features the groundbreaking diagnostic breast cancer imaging technology introduced by Seno Medical Instruments™, Inc. (Seno Medical). This technology might not only help physicians better differentiate between benign and malignant breast lesions, but also discriminate between breast cancer molecular subtypes.

The retrospective European post-marketing surveillance analysis corroborates previous studies, which concluded that opto-acoustic ultrasound (OA/US) technology might increase specificity and the ability to rule out disease, potentially reducing the number of false positive examinations and biopsies of benign masses. Researchers observed results from five centers in the Netherlands, where the technology has been introduced commercially using Seno Medical's Imagio® Breast Imaging System. In this study, 67 biopsy-proven malignant masses were reviewed to compare OA/US characteristics and histopathological prognostic indicators.

OA/US technology creates a "blood map" that gives functional and anatomical information in and around the mass using hemoglobin as a natural contrast agent. The study results showed that OA/US can also help identify different subtypes of cancer by measuring the emergence of angiogenesis (newly created blood vessels which indicate the presence of malignant activity within and around the mass). Other key factors (e.g. histologic grade, continuous number of mitosis, HER2 and hormone receptor status, and Ki-67 poliferation index) might also be identified with the aid of this technology.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

According to the study results, the combination of functional and morphologic information provided by OA/US showed promise in differentiating Luminal A, Luminal B, HER2-enriched, and Triple Negative cancers. These tumors have a different prognosis and require different treatment paths that physicians and patients must consider. Molecular analysis requires specialized equipment and expertise, making this process lengthy and expensive. Breast tumors are heterogeneous and biopsy may be insufficient to assess the complete tumor heterogeneity. Therefore, OA/US features that suggest an aggressive tumor subtype that is potentially conflicting with histopathologic biomarkers might suggest the need for more extensive review and inspection of the pathologic specimen.

You Must Be Logged In To Post A Comment